3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 7
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796,95k | N/D | 1968 |
Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610,23k | N/D | 1964 |
Dr. Dansu Li Ph.D. | Head of Technology | N/D | N/D | N/D |
Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | N/D | N/D | 1957 |
Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | N/D | N/D | 1968 |
Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | N/D | N/D | N/D |
Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | N/D | N/D | 1962 |
Dr. Nadeem Q. Mirza M.D., M.P.H. | Chief Medical Officer | N/D | N/D | N/D |
Ms. Andrea Epstein | Controller | N/D | N/D | N/D |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
L'ISS Governance QualityScore di Aprea Therapeutics, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 9.